Physician profile
Joseph E Vaccarella
NPI 1366417727
$9,859.71
in general payments reported to CMS, 2019-2025
57 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $1,029 · 2021: $1,754 · 2022: $1,592 · 2023: $1,684 · 2024: $1,639 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,011 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,011.33 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,418.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,295.57 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $618.44 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $597.04 | 2019-2025 | |
| Lilly USA, LLC | $570.14 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.38 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $504.94 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $357.72 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $344.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $311.61 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $302.89 | 2019-2024 | Belsomra, Steglatro, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $295.27 | 2019-2025 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.31 | 2019-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $239.75 | 2019-2021 | Xyosted, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $236.40 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vaccarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.